1. Home
  2. NCMI vs TRDA Comparison

NCMI vs TRDA Comparison

Compare NCMI & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$2.46

Market Cap

244.6M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.56

Market Cap

275.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
TRDA
Founded
2005
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.6M
275.3M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
NCMI
TRDA
Price
$2.46
$7.56
Analyst Decision
Buy
Strong Buy
Analyst Count
4
3
Target Price
$5.63
$21.00
AVG Volume (30 Days)
1.6M
226.0K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
3.36%
N/A
EPS Growth
52.17
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
$11.20
$39.97
Revenue Next Year
$6.22
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.16
$5.02
52 Week High
$5.03
$16.45

Technical Indicators

Market Signals
Indicator
NCMI
TRDA
Relative Strength Index (RSI) 34.71 55.84
Support Level $2.16 $5.71
Resistance Level $3.74 $7.95
Average True Range (ATR) 0.12 0.42
MACD 0.02 -0.01
Stochastic Oscillator 18.39 74.76

Price Performance

Historical Comparison
NCMI
TRDA

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: